Buy Rating Reiterated on Robust Cretostimogene Data and De-Risked Phase 2 Program; $100 Price Target Maintained

In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on CG Oncology, Inc., with a price target of $100.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors, including compelling early clinical data and a clear path toward broader development. He highlights that cretostimogene combined with gemcitabine in the CORE-008 Cohort CX study delivered robust high-grade event-free survival rates and strong complete response signals, while maintaining a favorable safety and tolerability profile in a predominantly community-based U.S. population.

He also emphasizes that the mechanistic rationale for pairing an oncolytic virus with a cytotoxic agent is supported by preclinical synergy data, positioning cretostimogene as a potential intravesical backbone therapy rather than a stand-alone product. Furthermore, he views the multi-cohort Phase 2 program design and the practical advantages of the sequential dosing schedule as incrementally de-risking the program, supporting an unchanged $100 price target as the company advances toward longer-term durability readouts and potential commercial relevance in high-risk NMIBC.

In another report released on May 16, LifeSci Capital also maintained a Buy rating on the stock with a $108.00 price target.